| dbo:abstract
|
- جيفوكيزوماب هو جسم مضاد وحيد النسيلة مأنسن لعلاج السكري وبعض الأمراض الالتهاببية. طورت جيفوكيزوماب شركة اسمها: XOMA US LLC. (ar)
- Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. On August 25, 2017, XOMA Corporation licensed the global commercial rights to gevokizumab to Novartis. Under the license agreement, Novartis will have worldwide rights to gevokizumab, and will be solely responsible for the development and commercialization of antibodies and products containing antibodies arising from gevokizumab. XOMA received an approximately $16 million upfront payment, and Novartis repaid in its entirety the approximately €12 million of debt owed by XOMA to Les Laboratoires Servier. XOMA is eligible to receive up to $438 million in development, regulatory and commercial milestones plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab. (en)
- Le gevokizumab (ou XOMA 052) est un anticorps monoclonal dirigé contre la fraction bêta de l'interleukine 1 et en cours de test comme médicament, administrée sous forme d'injection mensuelle. Il est encours de test dans le diabète de type 1 et de type 2, la polyarthrite rhumatoïde et dans les maladies cardio-vasculaires. Lors des formes résistantes d'uvéites de la maladie de Behcet, il permet l'amélioration des symptômes. Il améliore l'équilibre glycémique lors d'un diabète de type 2. (fr)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 3126 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:mabType
| |
| dbp:n
| |
| dbp:o
| |
| dbp:s
| |
| dbp:source
| |
| dbp:target
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- جيفوكيزوماب هو جسم مضاد وحيد النسيلة مأنسن لعلاج السكري وبعض الأمراض الالتهاببية. طورت جيفوكيزوماب شركة اسمها: XOMA US LLC. (ar)
- Le gevokizumab (ou XOMA 052) est un anticorps monoclonal dirigé contre la fraction bêta de l'interleukine 1 et en cours de test comme médicament, administrée sous forme d'injection mensuelle. Il est encours de test dans le diabète de type 1 et de type 2, la polyarthrite rhumatoïde et dans les maladies cardio-vasculaires. Lors des formes résistantes d'uvéites de la maladie de Behcet, il permet l'amélioration des symptômes. Il améliore l'équilibre glycémique lors d'un diabète de type 2. (fr)
- Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. (en)
|
| rdfs:label
|
- جيفوكيزوماب (ar)
- Gevokizumab (en)
- Gevokizumab (fr)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
